Hepion Pharma receives Nasdaq delisting notice due to stockholder deficit and failure to meet listing alternatives

Hepion Pharmaceuticals, Inc.

Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.
Company fails to meet alternatives: $35M market value or $500K net income in recent fiscal years.
Nasdaq gives 45 days to submit a compliance plan; extension of up to 180 days possible.
Common stock (HEPA) continues trading on Nasdaq Capital Market while cure process is pending.
No assurance that listing will be maintained; potential for hearing panel appeal if plan rejected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.